Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22284883 | 0.91 | MDM4 (0.42) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL17531773 | 0.91 | MDM4 (0.42) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL20764467 | 0.88 | MDM4 (0.43) | MDM4TP53CASP3MDM2EPHX2 | |
| SCHEMBL20764469 | 0.88 | MDM4 (0.43) | MDM4TP53CASP3MDM2EPHX2 | |
| SCHEMBL30302156 | 0.85 | MDM4 (0.39) | MDM4TP53PTPN1CASP3MDM2 | |
| SCHEMBL30392223 | 0.85 | MDM4 (0.41) | MDM4TP53CASP3MDM2EPHX2 | |
| SCHEMBL8227141 | 0.84 | MDM4 (0.50) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29594836 | 0.84 | MDM4 (0.50) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL14242960 | 0.83 | HDAC1 (0.47) | MDM4TP53PTPN1CASP3TNF | |
| SCHEMBL16582479 | 0.83 | HDAC1 (0.47) | MDM4TP53PTPN1CASP3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | CD4, MET, TNFSF10 | MDM4 1169/4885TP53 15/4885PTPN1 2266/4885 |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | MET, ARG1, CD4 | MDM4 1412/4885TP53 7/4885PTPN1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.